Novo Nordisk Pushes Forward with IcoSema Despite FDA Setback

Despite a recent setback with the FDA, Novo Nordisk is pushing ahead with its combination treatment, IcoSema, which pairs the once-weekly insulin icodec with the GLP-1 drug semaglutide. After a positive outcome in the late-stage COMBINE 1 trial, Novo plans to file an FDA application for IcoSema in the second half of 2024. The combo treatment aims to offer an improved option for Type 2 diabetes patients by enhancing blood sugar control and reducing weight.

The COMBINE 1 trial demonstrated that IcoSema outperformed insulin icodec alone in reducing A1c levels, a key marker for blood sugar control, with a decrease of 1.6% compared to 0.9% with icodec. Additionally, IcoSema led to an average weight loss of 3.7 kg, compared to a 1.9-kg weight gain in the insulin-only group. The study also reported a lower incidence of major hypoglycemia events in patients using IcoSema, highlighting its safety and potential efficacy.

However, the road to approval hasn't been smooth. The FDA recently issued a complete response letter for insulin icodec, citing concerns over its manufacturing process and potential risks of low blood sugar. Despite this hurdle, Novo Nordisk remains committed to advancing IcoSema, while facing competition from Eli Lilly's own once-weekly insulin candidate, which has shown promising results in its trials.